Advertisement

Esophagus

pp 1–8 | Cite as

Prognosis and prognostic factors of esophageal spindle cell carcinoma treated by esophagectomy: a retrospective single-institution analysis

  • Masashi HashimotoEmail author
  • Hidehiko Kitagami
  • Hiroki Niwa
  • Tomohiro Kikkawa
  • Tomoyuki Ohuchi
  • Toshinao Takenouchi
  • Masao Hosokawa
Original Article
  • 21 Downloads

Abstract

Background

Esophageal spindle cell carcinoma (ESpCC) is a malignant tumor composed of sarcomatous components. ESpCC is treated as a squamous cell carcinoma. However, because ESpCC is a rare tumor, little is known regarding its prognosis. This study aimed to analyze patients with ESpCC who were surgically treated at our hospital, determine the validity of surgery, and identify factors that indicate a prognosis.

Methods

Treatment characteristics, overall survival (OS), and recurrence-free survival (RFS) of 28 patients with ESpCC who underwent surgery at our hospital between 1990 and 2016 were assessed. Furthermore, factors associated with OS and RFS were analyzed.

Results

Subtotal esophagectomy with 3-field lymph node dissection and lower esophagectomy with 2-field lymph node dissection were performed in 25 and 3 patients, respectively. Chemotherapy was administered as preoperative therapy to two patients. Postoperative therapy, comprising radiotherapy and chemotherapy, was administered to three and nine patients, respectively. The 3- and 5-year RFS were 66.4% and 61.6% and the 3- and 5-year OS were 73% and 61.9%, respectively. Macroscopic type was identified as a prognostic factor. In terms of OS, prognosis was significantly worse in ulcerative-type ESpCC than in the polypoid type.

Conclusion

The 5-year OS of ESpCC mainly treated with surgical therapy was 61.9%. However, prognosis was poor in some patients with ulcerative-type ESpCC according to macroscopic type. In the future, it will be necessary to accumulate more cases and investigate therapeutic strategies added to surgery to improve prognosis.

Keywords

Spindle cell carcinoma Carcinosarcoma Esophageal cancer 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Human rights statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This study was approved by an ethical review board in Keiyukai Sapporo Hospital.

Informed consent

Informed consent or substitute for it was obtained from all patients for being included in the study.

References

  1. 1.
    Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumor of the digestive tumors, vol 3. 4th ed. Lyon: International Agency for Research on Cancer; 2010. p. 15–44.Google Scholar
  2. 2.
    Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRefGoogle Scholar
  3. 3.
    Katsuya Y, Honma Y, Taniguchi H, et al. Clinicopathological features and pathological evaluation of preoperative treatment of patients with resectable esophageal carcinosarcoma. Esophagus. 2017;14:317–23.CrossRefGoogle Scholar
  4. 4.
    Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumors. 7th ed. Hoboken: Wiley-Blackwell; 2010. p. 66–72.Google Scholar
  5. 5.
    Japan Esophageal S. Japanese Classification of Esophageal Cancer, 11th Edition: part II and III. Esophagus. 2017;14:37–65.CrossRefGoogle Scholar
  6. 6.
    Iyomasa S, Kato H, Tachimori Y, et al. Carcinosarcoma of the esophagus: a twenty-case study. Jpn J Clin Oncol. 1990;20:99–106.Google Scholar
  7. 7.
    Wang L, Lin Y, Long H, et al. Esophageal carcinosarcoma: a unique entity with better prognosis. Ann Surg Oncol. 2013;20:997–1004.CrossRefGoogle Scholar
  8. 8.
    Zhang B, Xiao Q, Yang D, et al. Spindle cell carcinoma of the esophagus: a multicenter analysis in comparison with typical squamous cell carcinoma. Medicine (Baltimore). 2016;95:e4768.CrossRefGoogle Scholar
  9. 9.
    Yu Z, Cheng BC, Chang S, et al. Clinicopathological analysis of esophageal carcinosarcoma: a report of 22 cases. Zhonghua Wei Chang Wai Ke Za Zhi. 2008;11:235–7.Google Scholar
  10. 10.
    Zhang BH, Yang WJ, Wang YG, et al. Clinical manifestation and prognosis of the surgical treatment of esophageal carcinosarcoma. Zhonghua Wai Ke Za Zhi. 2012;50:256–9.Google Scholar
  11. 11.
    Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive Registry of esophageal cancer in Japan, 2010. Esophagus. 2017;14:189–214.CrossRefGoogle Scholar
  12. 12.
    Chino O, Kijima H, Shimada H, et al. Clinicopathological studies of esophageal carcinosarcoma: analyses of its morphological characteristics using endoscopic, histological, and immunohistochemical procedures. Endoscopy. 2000;32:706–11.CrossRefGoogle Scholar
  13. 13.
    Kobayashi D, Koike M, Kodera Y, et al. Carcinosarcoma of the esophagus treated with chemoradiotherapy: report of four cases. Esophagus. 2010;7:119–25.CrossRefGoogle Scholar
  14. 14.
    Zuiki T, Hosoya Y, Ui T, et al. Therapeutic effectiveness of chemoradiotherapy for carcinosarcoma of the esophagus: two case reports and a review of the literature. Esophagus. 2009;6:189–95.CrossRefGoogle Scholar

Copyright information

© The Japan Esophageal Society and Springer 2019

Authors and Affiliations

  1. 1.Department of SurgeryKeiyukai Sapporo HospitalSapporo-CityJapan
  2. 2.Department of PathologyKeiyukai Sapporo HospitalSapporoJapan

Personalised recommendations